Omeprazole
- TRADE NAMES: Antra; Audazol; Gastroloc; Inhibitron; Logastric; Losec; Mopral; Omed; Ozoken; Parizac; Prilosec (AstraZeneca); Ulsen; Yosprala (Aralez)
- INDICATIONS: Duodenal ulcer, gastric ulcer, gastroesophageal reflux disease (GERD), erosive esophagitis
- CLASS: CYP1A2 inducer, Proton pump inhibitor (PPI)
- HALF-LIFE: 0.5–1 hour
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amoxicillin, Atazanavir, Bendamustine, Benzodiazepines, Cilostazol, Clarithromycin, Clobazam, Clopidogrel, Clozapine, Coumarins, Cyclosporine, Dasatinib, Delavirdine, Diazepam, Digoxin, Disulfiram, Emtricitabine/Rilpivirine/Tenofovir Alafenamide, Enzalutamide, Erlotinib, Escitalopram, Itraconazole, Ketoconazole, Lapatinib, Letermovir, Methotrexate, Nelfinavir, Phenytoin, Posaconazole, Prednisone, Raltegravir, Rilpivirine, Saquinavir, Selpercatinib, Sofosbuvir & Velpatasvir, Sotorasib, St John's Wort, Tacrolimus, Tipranavir, Ulipristal, Voriconazole, Warfarin
PREGNANCY CATEGORY: C
Yosprala is omeprazole and aspirin.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 05/08/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
